Banque Pictet & Cie SA maintained its position in shares of ChemoCentryx, Inc. (NASDAQ:CCXI) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,178 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Banque Pictet & Cie SA owned 0.11% of ChemoCentryx worth $507,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of CCXI. Vanguard Group Inc. increased its holdings in ChemoCentryx by 4.1% during the 1st quarter. Vanguard Group Inc. now owns 1,198,730 shares of the biopharmaceutical company’s stock worth $8,727,000 after purchasing an additional 47,475 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in ChemoCentryx during the 1st quarter worth $189,000. Russell Investments Group Ltd. increased its holdings in ChemoCentryx by 51.5% during the 1st quarter. Russell Investments Group Ltd. now owns 94,165 shares of the biopharmaceutical company’s stock worth $686,000 after purchasing an additional 31,997 shares during the period. BB&T Securities LLC purchased a new position in ChemoCentryx during the 2nd quarter worth $781,000. Finally, Wedge Capital Management L L P NC purchased a new position in ChemoCentryx during the 2nd quarter worth $424,000. Hedge funds and other institutional investors own 50.12% of the company’s stock.
Several analysts have issued reports on the company. Cowen and Company reaffirmed a “hold” rating on shares of ChemoCentryx in a research report on Tuesday, August 8th. Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Monday, July 17th. Finally, BidaskClub lowered ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Friday, August 18th.
WARNING: This piece was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://baseballnewssource.com/markets/banque-pictet-cie-sa-has-507000-position-in-chemocentryx-inc-ccxi/1580889.html.
In other ChemoCentryx news, insider Petrus Bekker sold 30,000 shares of the stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $9.98, for a total value of $299,400.00. Following the completion of the sale, the insider now directly owns 65,963 shares of the company’s stock, valued at approximately $658,310.74. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 223,649 shares of company stock valued at $2,157,360 over the last three months. Insiders own 26.80% of the company’s stock.
ChemoCentryx, Inc. (NASDAQ:CCXI) opened at 7.29 on Thursday. The stock’s market cap is $355.07 million. ChemoCentryx, Inc. has a 52 week low of $5.01 and a 52 week high of $10.80. The company has a 50 day moving average price of $7.65 and a 200 day moving average price of $7.76.
ChemoCentryx (NASDAQ:CCXI) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.02). The business had revenue of $8.94 million for the quarter. Analysts expect that ChemoCentryx, Inc. will post ($0.90) EPS for the current fiscal year.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with our FREE daily email newsletter.